Quarterly report [Sections 13 or 15(d)]

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)

v3.25.1
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)
9 Months Ended
Mar. 31, 2025
Notes Tables  
Schedule of the Consolidated Changes in Equity

Consolidated Changes in Equity (amounts in thousands):

    

Bio-Techne Shareholders    

    

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

Loss

Total

Balances at June 30, 2024

 

158,216

$

1,582

$

820,337

$

1,325,247

$

(78,316)

$

2,068,850

Net earnings

 

 

 

33,600

 

 

33,600

Other comprehensive income

 

 

 

 

18,229

 

18,229

Common stock issued for exercise of options

 

577

 

6

 

23,224

 

(2,338)

 

 

20,892

Common stock issued for restricted stock awards

 

50

1

 

1

 

(2,646)

 

 

(2,644)

Cash dividends

 

 

 

(12,688)

 

 

(12,688)

Stock-based compensation expense

 

 

 

10,146

 

 

 

10,146

Common stock issued to employee stock purchase plan

 

35

0

 

2,227

 

 

 

2,227

Employee stock purchase plan expense

38

38

Balances at September 30, 2024

 

158,878

$

1,589

$

855,973

$

1,341,175

$

(60,087)

$

2,138,650

Net earnings

 

34,890

 

34,890

Other comprehensive (loss)

(25,563)

(25,563)

Share repurchases

 

(1,118)

(11)

(75,617)

 

(75,628)

Common stock issued for exercise of options

 

132

1

5,183

(20)

 

5,164

Common stock issued for restricted stock awards

 

24

0

0

(993)

 

(993)

Cash dividends

 

(12,736)

 

(12,736)

Stock-based compensation expense

 

14,335

 

14,335

Employee stock purchase plan expense

373

373

Balances at December 31, 2024

 

157,916

$

1,579

$

875,864

$

1,286,699

$

(85,650)

$

2,078,492

Net earnings

22,588

22,588

Other comprehensive income

3,598

3,598

Share repurchases

(1,489)

(15)

(100,031)

(100,046)

Common stock issued for exercise of options

282

3

12,628

12,631

Common stock issued for restricted stock awards

9

1

1

(291)

(289)

Cash dividends

(12,580)

(12,580)

Stock-based compensation expense

11,355

11,355

Common stock issued to employee stock purchase plan

43

0

2,241

2,241

Employee stock purchase plan expense

35

35

Balances at March 31, 2025

 

156,761

$

1,568

$

902,124

$

1,196,385

$

(82,052)

$

2,018,025

    

Bio-Techne Shareholders    

    

  

Accumulated

Additional

Other

Common Stock

Paid-in

Retained

Comprehensive

Shares

Amount

Capital

Earnings

Loss

Total

Balances at June 30, 2023

 

157,642

$

1,576

$

721,543

$

1,309,461

$

(66,064)

$

1,966,516

Net earnings

 

 

 

50,993

 

 

50,993

Other comprehensive loss

 

 

 

 

(11,952)

 

(11,952)

Common stock issued for exercise of options

 

633

 

6

 

12,877

 

(15,460)

 

 

(2,577)

Common stock issued for restricted stock awards

 

47

1

 

0

 

(4,768)

 

 

(4,767)

Cash dividends

 

 

 

(12,654)

 

 

(12,654)

Stock-based compensation expense

 

 

 

9,981

 

 

 

9,981

Common stock issued to employee stock purchase plan

 

33

1

 

2,093

 

 

 

2,094

Employee stock purchase plan expense

112

112

Balances at September 30, 2023

 

158,355

$

1,584

$

746,606

$

1,327,572

$

(78,016)

$

1,997,746

Net earnings

 

27,465

 

27,465

Other comprehensive income

14,355

14,355

Share repurchases

 

(1,397)

(14)

(80,028)

 

(80,042)

Common stock issued for exercise of options

 

157

1

4,914

(1,074)

 

3,841

Common stock issued for restricted stock awards

 

27

0

0

 

0

Cash dividends

 

(12,559)

 

(12,559)

Stock-based compensation expense

 

12,413

 

12,413

Employee stock purchase plan expense

340

340

Balances at December 31, 2023

 

157,142

$

1,571

$

764,273

$

1,261,376

$

(63,661)

$

1,963,559

Net earnings

 

49,059

 

 

49,059

Other comprehensive loss

 

 

(11,646)

 

(11,646)

Common stock issued for exercise of options

 

372

 

4

 

15,761

 

 

 

15,765

Common stock issued for restricted stock awards

 

4

 

0

 

0

 

(168)

 

 

(168)

Cash dividends

 

 

 

(12,579)

 

 

(12,579)

Stock-based compensation expense

 

 

8,053

 

 

 

8,053

Common stock issued to employee stock purchase plan

36

1

2,251

2,252

Employee stock purchase plan expense

 

 

80

 

 

 

80

Balances at March 31, 2024

 

157,554

$

1,576

$

790,418

$

1,297,688

$

(75,307)

$

2,014,375

Schedule of changes in Accumulated Other Comprehensive Income (Loss)

Three months ended March 31, 2025 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of December 31, 2024, net of tax

$

5,030

$

(90,680)

$

(85,650)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

(3,079)

4,807

1,728

Amounts reclassified out

1,790

660

2,450

Total other comprehensive income (loss), before tax

(1,289)

5,467

4,178

Tax (expense)/benefit

(424)

(156)

(580)

Total other comprehensive income (loss), net of tax

 

(1,713)

5,311

3,598

Balance as of March 31, 2025, net of tax

$

3,317

$

(85,369)

$

(82,052)

Three months ended March 31, 2024 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of December 31, 2023 net of tax:

$

8,842

$

(72,503)

$

(63,661)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

(1,626)

(12,620)

(14,246)

Amounts reclassified out

2,570

837

3,407

Total other comprehensive income (loss), before tax

944

(11,783)

(10,839)

Tax (expense)/benefit

(609)

(198)

(807)

Total other comprehensive income (loss), net of tax

 

335

(11,981)

(11,646)

Balance as of March 31, 2024, net of tax

$

9,177

$

(84,484)

$

(75,307)

Nine months ended March 31, 2025 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2024, net of tax:

$

8,102

$

(86,418)

$

(78,316)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

(9,778)

(555)

(10,333)

Amounts reclassified out

6,544

2,102

8,646

Total other comprehensive income (loss), before tax

(3,234)

1,547

(1,687)

Tax (expense)/benefit

(1,551)

(498)

(2,049)

Total other comprehensive income (loss), net of tax

 

(4,785)

1,049

(3,736)

Balance as of March 31, 2025, net of tax(1)

$

3,317

$

(85,369)

$

(82,052)

Nine months ended March 31, 2024 (in thousands):

Unrealized

Gains

Foreign 

(Losses) on

Currency

Derivative

Translation 

    

Instruments

    

Adjustments

    

Total

Balance as of June 30, 2023, net of tax:

$

12,862

$

(78,926)

$

(66,064)

Other comprehensive income (loss), before tax:

Amounts before reclassifications

(9,582)

(7,368)

(16,950)

Amounts reclassified out

7,729

2,372

10,101

Total other comprehensive income (loss), before tax

(1,853)

(4,996)

(6,849)

Tax (expense)/benefit

(1,832)

(562)

(2,394)

Total other comprehensive income (loss), net of tax

 

(3,685)

(5,558)

(9,243)

Balance as of March 31, 2024, net of tax(1)

$

9,177

$

(84,484)

$

(75,307)

(1) The Company had a net deferred tax liability for its cash flow hedge of $1.0 million and $2.9 million as of March 31, 2025 and 2024, respectively.